Overview

A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-141 at varying dose levels and frequencies.
Phase:
Phase 1
Details
Lead Sponsor:
Merrimack Pharmaceuticals